Pediatric Medicine
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Access global pediatric medicine market intelligence. Discover drug development, regulatory insights, and investment opportunities for children's health.
Showing 1–10 of 10 articles
Quick answer
NovaPharmaNews Pediatric Medicine hub for FDA covers 10 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen in McCune-Albright Syndrome
Laguna Biotherapeutics Receives FDA Clearance for LGNA-100 Pediatric Leukemia Trial
Novartis Coartem Baby Receives WHO Prequalification as First Malaria Treatment for Newborns
BrioHealth Solutions Receives FDA Conditional Approval for Pediatric BrioVAD Heart Device Trial
Novo Nordisk's Oral Semaglutide Shows Promise as First GLP-1 Therapy for Children with Type 2 Diabetes
Dupixent Becomes First Biologic Approved for Chronic Spontaneous Urticaria in Children Ages 2-11
Dupixent Becomes First Biologic Approved for Children Ages 2-11 with Chronic Spontaneous Urticaria
Sanofi's Tzield Approved by FDA for Children as Young as 1 Year to Delay Type 1 Diabetes Progression
FDA Approves Sanofi's Tzield for Children Age 1+ to Delay Type 1 Diabetes Onset
FDA Approves RAPIBLYK (Landiolol) for Pediatric Supraventricular Tachycardia - AOP Health US Expands Critical Care Treatment Options
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.